AgomAb Therapeutics NV Statistics
Total Valuation
AGMB has a market cap or net worth of $518.56 million. The enterprise value is $376.90 million.
Important Dates
The last earnings date was Thursday, April 23, 2026, after market close.
| Earnings Date | Apr 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AGMB has 48.74 million shares outstanding. The number of shares has increased by 2,064.50% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 48.74M |
| Shares Change (YoY) | +2,064.50% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.09% |
| Owned by Institutions (%) | 24.74% |
| Float | 25.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.15 |
| P/TBV Ratio | 4.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.52, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.52 |
| Quick Ratio | 6.27 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -445.68 |
Financial Efficiency
Return on equity (ROE) is -39.22% and return on invested capital (ROIC) is -23.03%.
| Return on Equity (ROE) | -39.22% |
| Return on Assets (ROA) | -20.58% |
| Return on Invested Capital (ROIC) | -23.03% |
| Return on Capital Employed (ROCE) | -43.87% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.27M |
| Employee Count | 58 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 12.73 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 43.65 |
| Average Volume (20 Days) | 220,027 |
Short Selling Information
The latest short interest is 433,265, so 0.89% of the outstanding shares have been sold short.
| Short Interest | 433,265 |
| Short Previous Month | 257,073 |
| Short % of Shares Out | 0.89% |
| Short % of Float | 1.69% |
| Short Ratio (days to cover) | 2.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -69.60M |
| Pretax Income | -73.44M |
| Net Income | -73.44M |
| EBITDA | -69.34M |
| EBIT | -69.60M |
| Earnings Per Share (EPS) | -$135.71 |
Full Income StatementBalance Sheet
The company has $136.80 million in cash and $1.47 million in debt, giving a net cash position of $135.33 million or $2.78 per share.
| Cash & Cash Equivalents | 136.80M |
| Total Debt | 1.47M |
| Net Cash | 135.33M |
| Net Cash Per Share | $2.78 |
| Equity (Book Value) | 153.69M |
| Book Value Per Share | 73.56 |
| Working Capital | 120.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$60.75 million and capital expenditures -$4,696, giving a free cash flow of -$60.60 million.
| Operating Cash Flow | -60.75M |
| Capital Expenditures | -4,696 |
| Depreciation & Amortization | 256,464 |
| Net Borrowing | -395,822 |
| Free Cash Flow | -60.60M |
| FCF Per Share | -$1.24 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |